Clinical Trial

A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The primary objective of this trial is to evaluate the pharmacokinetics of a single subcutaneous (SC) dose of AMG 133 in participants with various degrees of renal impairment compared to participants with normal renal function.
Trial Details
NCT Number NCT07429045
Lead Sponsor Amgen
Conditions Overweight and Obesity
Enrollment 44 participants
Start Date 2025-03-11
Primary Completion 2025-11-21 (estimated)
Study Completion 2025-11-21 (estimated)
Updated on ClinicalTrials.gov 2026-02-24